Fierce Pharma February 21, 2024
Four major drugmakers are joining forces as they prepare to battle certain aspects of the Inflation Reduction Act (IRA) in court next month.
Tuesday, a federal judge in New Jersey agreed to let Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson present oral arguments together in their bid to challenge the IRA’s Medicare negotiations framework, which will allow Medicare to bargain over the costs of certain drugs beginning in 2026.
Arguments from all four companies are set to be heard over a single day on March 7, according to a court docket entry from Tuesday. Endpoints News was first to report the development.
While there are nuances to each company’s arguments, the defendants figure the hearing should be...
Today's Sponsors
Today's Sponsor